Pro Dex Inc (PDEX) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Pro Dex Inc (PDEX) stock forecast summary
Our AI ranks Pro Dex Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Pro Dex Inc is a small-cap company with a market capitalization of $192M. It ranks number 60 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For PDEX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.6%, buy ≥ +3.2%, sell < +1.9%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PDEX included.
Follow PDEX freePDEX price chart and AI forecast
How PDEX ranks among 5121 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Pro Dex Inc (PDEX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | PDEX | Rank |
|---|---|---|
| Market Cap | $192M | 60/60 |
| P/E Ratio | 14.53x | 22/25 |
| P/B Ratio | 4.02x | 33/55 |
| EPS | $4.12 | – |
| Book Value/Share | $14.87 | – |
| Revenue/Share | $24.21 | – |
| FCF/Share | $2.11 | – |
Profitability & Margins
| Metric | PDEX | Rank |
|---|---|---|
| ROE | 28.7% | 4/40 |
| ROA | 18.3% | 2/43 |
| ROIC | 21.1% | 7/52 |
| Gross Margin | 31.4% | 49/52 |
| Operating Margin | 16.8% | 13/53 |
| Net Margin | 17.6% | 5/42 |
| EBT Margin | 23.2% | 7/53 |
| Tax Rate | 24.2% | – |
Financial Health
| Metric | PDEX | Rank |
|---|---|---|
| Current Ratio | 4.10x | 29/58 |
| Quick Ratio | 2.45x | 28/54 |
| D/E Ratio | 0.56x | 28/55 |
| Financial Leverage | 1.56x | 27/53 |
| Interest Coverage | 15.2x | 8/48 |
| Working Capital | $40M | 54/58 |
Cash Flow
| Metric | PDEX | Rank |
|---|---|---|
| Operating Cash Flow | $7M | 33/54 |
| Free Cash Flow | $7M | 25/49 |
| Capital Spending | -$480K | 6/49 |
| FCF/Sales | 8.7% | 21/48 |
| CapEx/Sales | 0.6% | 43/48 |
Operational Efficiency
| Metric | PDEX | Rank |
|---|---|---|
| Asset Turnover | 1.04x | 6/49 |
| Receivables Turnover | 3.7x | 50/51 |
| Inventory Turnover | 2.5x | 17/50 |
| Fixed Assets Turnover | 14.4x | 11/51 |
| Days Sales Outstanding | 100 days | 2/51 |
| Days Inventory | 147 days | 34/50 |
| Payables Period | 29 days | 42/45 |
| Cash Conversion Cycle | 218 days | 17/42 |
Income Statement
| Metric | PDEX | Rank |
|---|---|---|
| Total Revenue | $78M | 46/51 |
| Operating Income | $13M | 24/54 |
| Net Income | $14M | 19/43 |
| R&D Expense | $3M | 51/52 |
| SG&A Expense | $8M | 53/53 |
| Cost of Goods Sold | $53M | 36/52 |
Dividend & Shareholder Information
| Metric | PDEX | Rank |
|---|---|---|
| Shares Outstanding | 3M | – |
| Net Income Growth | 52.2% | 4/13 |
| EPS Growth | 54.3% | 4/15 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $53M | 71.5% of assets |
| Cash & Short-term Investments | $8M | 11.0% of assets |
| Accounts Receivable | $21M | 28.5% of assets |
| Inventory | $21M | 28.8% of assets |
| Total Liabilities | $27M | 36.1% of assets |
| Short-term Debt | $9M | 11.7% of assets |
PDEX quarterly financials and insider trading
Pro Dex Inc (PDEX) industry peers
Companies classified under the same SEC industry code as Pro Dex Inc (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| PDEX Pro Dex Inc | ▲ | $192M |
| SYK Stryker Corp | ▼ | $108.02B |
| MMM 3m Co | ▼ | $84.82B |
| BSX Boston Scientific Corp | ▼ | $63.97B |
| BDX Becton Dickinson & Co | ▼ | $52.78B |
| MDLN Medline Inc. | ▶ | $47.24B |
| RMD Resmed Inc | ▼ | $33.94B |
| DXCM Dexcom Inc | ▼ | $33.10B |
| WST West Pharmaceutical Services Inc | ▼ | $26.37B |
| SOLV Solventum Corp | ▼ | $14.85B |
| BAX Baxter International Inc | ▶ | $13.32B |
| PEN Penumbra Inc | ▼ | $12.61B |
| GMED Globus Medical Inc | ▼ | $10.59B |
| GKOS Glaukos Corp | ▲ | $9.77B |
| PODD Insulet Corp | ▼ | $9.29B |
| STVN Stevanato Group S.P.A. | ▲ | $5.85B |
| HAE Haemonetics Corp | ▼ | $5.52B |
| TFX Teleflex Inc | ▼ | $5.22B |
| MMSI Merit Medical Systems Inc | ▼ | $5.20B |
| MMED Minimed Group, Inc. | ▶ | $4.73B |
| HTFL Heartflow, Inc. | ▲ | $4.43B |
| ICUI Icu Medical Inc/De | ▼ | $4.18B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.60B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.30B |
| ATRC Atricure, Inc. | ▶ | $2.94B |
| UFPT Ufp Technologies Inc | ▶ | $2.25B |
| INSP Inspire Medical Systems, Inc. | ▲ | $2.03B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.89B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.71B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.69B |
| NVCR Novocure Ltd | ▲ | $1.61B |
| DRTS Alpha Tau Medical Ltd. | ▲ | $1.19B |
| IRMD Iradimed Corp | ▼ | $1.14B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.11B |
| AORT Artivion, Inc. | ▼ | $1.07B |
| IART Integra Lifesciences Holdings Corp | ▶ | $1.05B |
| PRCT Procept Biorobotics Corp | ▲ | $1.00B |
| BVS Bioventus Inc. | ▼ | $943M |
| BBNX Beta Bionics, Inc. | ▲ | $913M |
| SIBN Si-Bone, Inc. | ▶ | $873M |
| SGP Spyglass Pharma, Inc. | ▲ | $792M |
| MDXG Mimedx Group, Inc. | ▶ | $685M |
| KIDS Orthopediatrics Corp | ▼ | $589M |
| SSII Ss Innovations International, Inc. | ▲ | $541M |
| DCTH Delcath Systems, Inc. | ▲ | $523M |
| TCMD Tactile Systems Technology Inc | ▶ | $508M |
| ANGO Angiodynamics Inc | ▲ | $487M |
| BWAY Brainsway Ltd. | ▲ | $463M |
| CERS Cerus Corp | ▲ | $455M |
| SGHT Sight Sciences, Inc. | ▲ | $454M |
| NPCE Neuropace Inc | ▶ | $431M |
| RCEL Avita Medical, Inc. | ▲ | $405M |
| CARL Carlsmed, Inc. | ▲ | $381M |
| OFIX Orthofix Medical Inc. | ▼ | $377M |
| EMBC Embecta Corp. | ▶ | $365M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $339M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $294M |
| ANIK Anika Therapeutics, Inc. | ▼ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $277M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $263M |
Where PDEX sits on the market map
Pro Dex Inc (PDEX) stock news
Loading...
Pro Dex Inc (PDEX) stock forecast FAQ
What is the Pro Dex Inc (PDEX) stock forecast?
Our AI ranks Pro Dex Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Pro Dex Inc stock predictions?
For PDEX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Pro Dex Inc forecasts updated?
Pro Dex Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Pro Dex Inc's industry peers?
60 issuers in our coverage, PDEX included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.